UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Mar

08

BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

Read More Share:linkedin| twitter| email

Mar

07

Innovating and collaborating in immuno-dermatology: a dialogue with UCB’s Simon Lucas & Camille Lee

Read More Share:linkedin| twitter| email

Mar

06

Putting People First to Create a More Sustainable Healthcare System

Read More Share:linkedin| twitter| email

Feb

28

UCB on Growth Path for a Decade Plus

Read More Share:linkedin| twitter| email

Feb

22

Rare Disease Day 2024: The Moment is Now to Be Patient-First to Deliver for People Living with Rare Diseases

Read More Share:linkedin| twitter| email

Feb

12

Harmony in Health: Partnering for Enhanced Seizure Management and Understanding

Read More Share:linkedin| twitter| email

Jan

11

Our Wish in 2024: Renewed Hope for People Living with Chronic Inflammatory Diseases

Read More Share:linkedin| twitter| email

Jan

03

ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive

Read More Share:linkedin| twitter| email

Dec

02

UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

Read More Share:linkedin| twitter| email

Dec

01

UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)